Author(s):
A.K. Sadanov, I.R. Kulmagambetov, F.N. Nurmanbetova, G. Zh. Sarsenbayeva, I.A. Ratnikova, S.Orazymbet, Ye.Zh. Shorabayev, B.B. Baimakhanova, L.Ye. Protasyuk, A.D. Massirbayeva
Email(s):
irina.ratn@gmail.com
DOI:
10.52711/0974-360X.2024.00613
Address:
A.K. Sadanov1, I.R. Kulmagambetov2, F.N. Nurmanbetova2, G. Zh. Sarsenbayeva2, I.A. Ratnikova2, S.Orazymbet2, Ye.Zh. Shorabayev2, B.B. Baimakhanova1, L.Ye. Protasyuk1, A.D. Massirbayeva2
1Scientific and Production Center of Microbiology and Virology LLP, Almaty, Kazakhstan.
2Industrial Microbiology LLP, Almaty, Kazakhstan.
*Corresponding Author
Published In:
Volume - 17,
Issue - 8,
Year - 2024
Cite this article:
A.K. Sadanov, I.R. Kulmagambetov, F.N. Nurmanbetova, G. Zh. Sarsenbayeva, I.A. Ratnikova, S.Orazymbet, Ye.Zh. Shorabayev, B.B. Baimakhanova, L.Ye. Protasyuk, A.D. Massirbayeva. First Phase of the Clinical trial of the AS-Probionorm Probiotic Medication for the treatment of Human Intestinal Infections. 2024; 17(8):39498-4. doi: 10.52711/0974-360X.2024.00613